Oncology · Medical Literature
[Comment] Cretostimogene grenadenorepvec: promise beyond response
Abstract
For patients with high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ, therapeutic decision making remains challenging. Radical cystectomy offers the most reliable oncological control, but at the cost of major surgery, urinary diversion, and lasting effects on quality of life. Bladder-sparing approaches are therefore attractive, particularly if they provide durable disease control without compromising the opportunity for cure. Against this backdrop, the results of BOND-003 Cohort C reported by Mark Tyson and colleagues in The Lancet Oncology enter a rapidly evolving treatment landscape.
Clinical relevance
In patients with high-risk, BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), does intravesical cretostimogene grenadenorepvec monotherapy achieve clinically meaningful and durable complete responses while preserving the bladder? __SNAPSHOT__ {"studyDesign":"Editorial Comment/Invited Commentary on a single-arm, Phase 3 trial (BOND-003 Cohort C; NCT04452591). The underlying trial being discussed is NOT a randomized controlled trial — it is an uncontrolled, single-arm, Phase 3 registration study.","setting":"41 academic and community urology sites across North America, Australia, and the Asia-Pacific region (international, multicenter)","sampleSize":"n=115 enrolled; n=112 received at least 1 dose; n=110 evaluable for efficacy (per primary analysis)","population":"Adults with pathologically confirmed high-risk, BCG-unresponsive NMIBC with CIS (with or without resected high-grade Ta or T1 disease); ECOG performance status 0–2; adequate organ function; ineligible for or having refused radical cystectomy. Median age 74 years. Heavily pretreated: median 12 prior intravesical BCG instillations (IQR 9–15). Prior therapies included intravesical gemcitabine–docetaxel and systemic pembrolizumab.","intervention":"Intravesical cretostimogene grenadenorepvec (oncolytic adenoviral immunotherapy targeting RB-E2F pathway-altered tumor cells) administered once weekly for 6 weeks (induction), with maintenance therapy and option for a second 6-week induction cycle for persistent high-grade disease at week 13","comparator":"Not applicable — single-arm trial; efficacy evaluated against a pre-specified historical response benchmark","primaryOutcome":"Complete response (CR) at any time (centrally confirmed)","followUp":"Median follow-up 25.8 months (data cutoff: June 23, 2025)","fundingSource":"Industry (CG Oncology, Inc.; NASDAQ: CGON — the drug developer and trial sponsor). This commentary is authored by independent academic clinicians, but the underlying trial is industry-funded."}
Key findings
The trial met its pre-specified primary endpoint with statistical significance. A centrally confirmed CR at any time was achieved in 83 of 110 evaluable patients (75.5%; 95% CI 66.3–83.2%), exceeding historical and contemporary benchmarks for this disease setting. Among responders, the estimated probability of remaining disease-free was 64.2% (95% CI 52.2–73.8%) at 12 months and 60.1% (95% CI 48.2–70.0%) at 24 months. Median duration of response (DOR) was at least 27.9 months and was ongoing at the data cutoff, with approximately 90% of patients in response at 12 months remaining in response at 24 months, and one patient disease-free beyond 51 months. Bladder-sparing outcomes were notable: cystectomy-free survival was approximately 89% at 12 months and 81% at 24 months. Progression to muscle-invasive bladder cancer (MIBC) was uncommon, with 96.6% of patients free from progression at both 48 and 96 weeks; only 3.4% of patients progressed during the study. Activity was observed across subgroups, including patients who had received prior intravesical gemcitabine–docetaxel or systemic pembrolizumab. Safety: treatment was characterized by transient grade 1–2 lower urinary tract symptoms; no grade 3 or 4 treatment-related adverse events and no treatment-related deaths were reported. Median adverse event resolution time was 1 day. NNT is not calculable from a single-arm study without a concurrent control arm. No head-to-head comparative efficacy statistics (relative risk, odds ratio, hazard ratio vs. an active comparator) were reported, as there was no randomized comparator.
Practice implications
This commentary contextualizes BOND-003 Cohort C results within the challenging therapeutic landscape of BCG-unresponsive NMIBC with CIS, where radical cystectomy remains the most reliable oncological intervention but carries substantial morbidity and quality-of-life impact. The trial established that cretostimogene grenadenorepvec monotherapy achieves a high any-time CR rate (75.5%) with a notable median DOR of at least 27.9 months and low MIBC progression rates in a heavily pretreated population — findings that appear clinically meaningful in this setting. What the trial did NOT establish: (1) superiority over any active comparator (no randomized arm); (2) an overall survival benefit; (3) long-term cure rates — DOR follow-up is maturing but not complete; (4) generalizability to patients who were fit for and willing to undergo cystectomy, as trial eligibility excluded or enriched for cystectomy-ineligible/refusing patients. The findings are most applicable to patients with BCG-unresponsive NMIBC-CIS who are ineligible for or decline radical cystectomy. Patients who are fit for and willing to consider cystectomy, or those with pure papillary (non-CIS) disease, were not the primary target population. As this summary is based principally on a published comment and industry press release data rather than the full peer-reviewed manuscript, some methodological details (e.g., exact statistical testing framework, pre-specified benchmark threshold, detailed subgroup analyses) are not directly confirmable. Cretostimogene has not yet received FDA approval; its safety and efficacy have not been formally established by any regulatory authority. This is not individualized treatment guidance. __LIMITATIONS__ 1. Single-arm design: absence of a randomized comparator precludes causal inference or formal efficacy comparisons; response rates are benchmarked against historical controls, which are subject to selection and ascertainment bias. 2. Moderate sample size (n=110 efficacy-evaluable), limiting precision of subgroup analyses. 3. Cystectomy-ineligible or cystectomy-refusing population: findings may not generalize to patients who are surgical candidates. 4. Industry sponsorship (CG Oncology): all primary data are controlled by the commercial developer; independent verification not yet established. 5. Primary endpoint is CR (a surrogate endpoint); overall survival and disease-specific survival data are immature and not reported. 6. No blinding possible given the single-arm, intravesical design, though central pathology review of CRs mitigates some ascertainment risk. 7. Median follow-up of only 25.8 months — DOR is ongoing; long-term durability beyond ~27 months is not yet fully characterized. 8. Generalizability limited by geographic enrollment (North America, Australia, Asia-Pacific) and highly pretreated patient characteristics (median 12 prior BCG instillations), which may not represent earlier-line BCG-unresponsive patients. 9. The source document is a journal comment/editorial — only limited data are available compared to the full primary publication; full statistical analysis plan, safety table, and exploratory endpoints are not directly accessible for this summary. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ BOND-003 Cohort C demonstrates that intravesical cretostimogene grenadenorepvec monotherapy achieves a high any-time CR rate (75.5%; 95% CI 66.3–83.2%) with a median DOR of at least 27.9 months and a favorable safety profile in patients with high-risk, BCG-unresponsive NMIBC-CIS who are unfit for or decline radical cystectomy. Progression to MIBC was uncommon (3.4%), and the majority of patients retained their bladders at 24 months. Pending FDA approval and longer-term survival data, these results position cretostimogene as a potentially practice-informing bladder-sparing option, though the absence of a randomized comparator and immaturity of survival endpoints preclude definitive practice-changing recommendations at this time.